EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND

Naveed Sattar iD, Hertzel C Gerstein iD, David D'Alessio, Deepak L Bhatt, John B Buse, Stefano Del Prato iD, Steven E Kahn, A Michael Lincoff, Darren K McGuire iD, Michael A Nauck iD, Steven E Nissen, Bernard Zinman iD und 9 weitere

Diabetes Care · 01.10.2026 · 49 (10) · 1771-1778

DOI: 10.2337/dc26-0298 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, online erschienen am 06.04.2026. Verfasst von Naveed Sattar und 20 weiteren Autor:innen. Beteiligte Einrichtung: School of Cardiovascular Medicine and Metabolic Health, University of Glasgow, Glasgow, U.K. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Tirzepatide. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE In prespecified analyses, the treatment effect for major adverse cardiovascular event (MACE) of tirzepatide compared with imputed placebo was estimated using SURPASS-Cardiovascular Outcomes Trial (SURPASS-CVOT) and Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) trial data. RESEARCH DESIGN AND METHODS The indirect comparison with placebo was conducted for primary (MACE-3) and secondary outcomes of SURPASS-CVOT. The analysis included data from REWIND participants who would have been eligible for SURPASS-CVOT and all participants from SURPASS-CVOT. Propensity score estimation was used to adjust for differences in participant characteristics between studies. The indirect analysis of the treatment effect was derived by multiplying the hazard ratio (HR) for MACE-3 between tirzepatide and dulaglutide in SURPASS-CVOT by the HR for dulaglutide versus placebo in REWIND. Sensitivity analyses were performed using unadjusted analyses, including both the selected REWIND and the entire REWIND populations, and adjusted analysis in the entire REWIND population. Post hoc sensitivity analyses used data from a recent glucagon-like peptide 1 receptor agonist (GLP-1RA) meta-analysis that included REWIND. RESULTS Analyses included 2,055 of 9,901 participants from REWIND and all 13,165 participants from SURPASS-CVOT. In indirect treatment effect comparisons, tirzepatide versus placebo was associated with lower MACE-3 (HR 0.72; 95% CI 0.55, 0.94), death from CV cause or heart failure events (HR 0.70; 95% CI 0.51, 0.96), and all-cause death (HR 0.61; 95% CI 0.45, 0.82). Sensitivity analyses, including nonadjusted or the entire REWIND cohort data or meta-analysis data for GLP-1RAs, were generally consistent. CONCLUSIONS In this indirect prespecified exploratory comparison, tirzepatide compared with imputed placebo was associated with reduced CV outcomes and all-cause mortality in participants with type 2 diabetes and established atherosclerotic CV disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesDiabetes Mellitus, Type 2Hypoglycemic AgentsTirzepatideGlucagon-Like Peptide-1 Receptor AgonistsAgedFemaleHumansMaleMiddle AgedGlucagon-Like PeptidesImmunoglobulin Fc FragmentsRecombinant Fusion Proteins

Substanzen

dulaglutideGlucagon-Like PeptidesHypoglycemic AgentsImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsTirzepatideGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • School of Cardiovascular Medicine and Metabolic Health, University of Glasgow, Glasgow, U.K.
  • Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
  • Duke University Medical Center, Durham, NC.
  • Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY.
  • University of North Carolina at Chapel Hill, Chapel Hill, NC.
  • Interdisciplinary Research Center "Health Science", Sant'Anna School of Advanced Studies, Pisa, Italy.

ORCID-Profile: Naveed Sattar, Hertzel C Gerstein, Stefano Del Prato, Darren K McGuire, Michael A Nauck, Bernard Zinman, Sophia Zoungas, Russell J Wiese, Stephen J Nicholls

Förderung

  • Eli Lilly and Company

Zitieren

APA

Sattar, N., Gerstein, H. C., D'Alessio, D., Bhatt, D. L., Buse, J. B., Del Prato, S., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Nauck, M. A., Nissen, S. E., Zinman, B., Zoungas, S., Bartee, A., Miller, D., Nishiyama, H., Qu, Y., Weerakkody, G., Wiese, R. J., …, & Nicholls, S. J. (2026). Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND. Diabetes Care, 49(10), 1771-1778. https://doi.org/10.2337/dc26-0298

Vancouver

Sattar N, Gerstein HC, D'Alessio D, Bhatt DL, Buse JB, Del Prato S, et al. Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND. Diabetes Care. 2026;49(10):1771-1778. doi:10.2337/dc26-0298

BibTeX
@article{Sattar2026,
  author = {Sattar, Naveed and Gerstein, Hertzel C and D'Alessio, David and Bhatt, Deepak L and Buse, John B and Del Prato, Stefano and Kahn, Steven E and Lincoff, A Michael and McGuire, Darren K and Nauck, Michael A and Nissen, Steven E and Zinman, Bernard and Zoungas, Sophia and Bartee, Amy and Miller, Debra and Nishiyama, Hiroshi and Qu, Yongming and Weerakkody, Govinda and Wiese, Russell J and Pavo, Imre and Nicholls, Stephen J},
  title = {Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND},
  journal = {Diabetes Care},
  year = {2026},
  volume = {49},
  number = {10},
  pages = {1771--1778},
  doi = {10.2337/dc26-0298}
}
Kostenlos starten →